For hormone receptor positive breast cancer, the development of endocrine resistance commonly occurs, presenting as either disease progression in the metastatic setting or recurrence during or following adjuvant endocrine therapy. Various mechanisms of resistance have been described. In order to reduce or overcome endocrine resistance, there has been substantial interest in developing potent and orally bioavailable selective estrogen receptor degraders (SERDs) for metastatic disease and select patients with early-stage estrogen receptor positive breast cancer.

中文翻译：

---

加速从晚期到早期乳腺癌的药物获取：口服选择性雌激素受体降解剂的特例。

对于激素受体阳性乳腺癌，通常会发生内分泌抗性的发展，表现为转移性环境中的疾病进展或辅助内分泌治疗期间或之后的复发。已经描述了各种抗性机制。为了减少或克服内分泌阻力，人们对开发有效的和口服生物可利用的选择性雌激素受体降解剂 (SERD) 治疗转移性疾病和选择患有早期雌激素受体阳性乳腺癌的患者产生了浓厚的兴趣。